Linagliptine Eg (Eurogenerics) Nv

Linagliptin, the active ingredient in Linagliptine Eg (Eurogenerics) Nv, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Linagliptine Eg (Eurogenerics) Nv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptine Eg acts on the incretin pathway to manage type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves overall glycaemic control by increasing insulin secretion and reducing glucagon release. - HbA1c reduction: helps lower glycated haemoglobin levels when added to diet and exercise. - Fasting plasma glucose: contributes to lower fasting glucose concentrations in patients with inadequate control on other oral agents.

Adverse reactions reported with linagliptin may vary in frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate head pain. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Dizziness: occasional sensation of light‑headedness. - Gastrointestinal discomfort: nausea or loose stools.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation. - Severe hypersensitivity reactions: including angioedema, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe joint pain: unexplained arthralgia that may require medical evaluation.

Linagliptine Eg should be used with attention to patient‑specific factors and storage conditions. - Renal impairment: monitor renal function; dose adjustment is not required but caution is advised. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: observe for any worsening of cardiac status. - Hypersensitivity: discontinue immediately if signs of severe allergic reaction appear. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Linagliptine Eg may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness. - Co‑administration with insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (especially thiazides): may potentiate hypoglycaemic episodes. - Antihypertensive agents: additive blood‑pressure lowering effect may occur. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor renal function when combined.